AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23063288 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater nursing staff time
Number of subjects: 0
Study 23063288 — intervention group
Group type: COMPARATOR
Intervention: Nursing home residents without dementia
Number of subjects: 0
Study 20619385 — intervention group
Group type: EXPERIMENTAL
Intervention: Compatible tool transformations
Number of subjects: 0
Study 20619385 — intervention group
Group type: EXPERIMENTAL
Intervention: Incompatible tool transformations
Number of subjects: 0
Study 18597602 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) treatment
Number of subjects: 16
Study 18597602 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated pockets)
Number of subjects: 16
Study 15795711 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (20 mEq over 20 minutes, followed by 20 mEq over 2 hours)
Number of subjects: 199
Study 15795711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 11850760 — intervention group
Group type: COMPARATOR
Intervention: Single drugs (amphetamine, benzphetamine, fenfluramine, sibutramine)
Number of subjects: 108
Study 11850760 — intervention group
Group type: COMPARATOR
Intervention: Combination drugs
Number of subjects: 108
Study 11850760 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall medications studied
Number of subjects: 108
Study 11850760 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine, benzphetamine, fenfluramine, sibutramine
Number of subjects: 108
Study 10329340 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention group (tailored skill building and facilitating activities to improve nutrition and increase physical activity)
Number of subjects: 4842
Study 10329340 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention group
Number of subjects: 4842
Study 10329340 — intervention group
Group type: COMPARATOR
Intervention: Minimum intervention group
Number of subjects: 4842
Study 7867055 — intervention group
Group type: EXPERIMENTAL
Intervention: Blackcurrant drink with 0.103% citrate
Number of subjects: 20
Study 7867055 — intervention group
Group type: COMPARATOR
Intervention: Plain blackcurrant drink
Number of subjects: 20
Study 7867055 — intervention group
Group type: COMPARATOR
Intervention: 10% sucrose (positive control)
Number of subjects: 20
Study 7867055 — intervention group
Group type: COMPARATOR
Intervention: 10% sorbitol (negative control)
Number of subjects: 20
Study 8444752 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-based intervention
Number of subjects: 20
Study 8444752 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based intervention
Number of subjects: 20
Study 3530226 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisynthetic human insulin (Novo)
Number of subjects: 20
Study 3530226 — intervention group
Group type: COMPARATOR
Intervention: Highly purified porcine insulin (Monocomponent)
Number of subjects: 20
Study 29462969 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mL of milk (MILK)
Number of subjects: 18
Study 26519688 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuanghua Baihe tablets
Number of subjects: 0
Study 25522565 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg by muscle injection 30 min before the operation
Number of subjects: 120
Study 25522565 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg
Number of subjects: 120
Study 25522565 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 120
Study 22426673 — intervention group
Group type: EXPERIMENTAL
Intervention: Real exposure to electromagnetic fields from mobile phones for 10 minutes
Number of subjects: 160
Study 22426673 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure to electromagnetic fields for 10 minutes
Number of subjects: 160
Study 20826258 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) systolic dysfunction
Number of subjects: 2416
Study 20826258 — intervention group
Group type: COMPARATOR
Intervention: No left ventricular (LV) systolic dysfunction
Number of subjects: 2416
Study 18446439 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher quality relationships with adult providers (characterized by trust, mutuality, and empathy)
Number of subjects: 0
Study 18446439 — intervention group
Group type: COMPARATOR
Intervention: Lower quality relationships with adult providers
Number of subjects: 0
Study 16001111 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 1.25 mg
Number of subjects: 0
Study 16001111 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 0
Study 12655514 — intervention group
Group type: EXPERIMENTAL
Intervention: One course of perioperative chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil
Number of subjects: 461
Study 12655514 — intervention group
Group type: EXPERIMENTAL
Intervention: Low p27 expression
Number of subjects: 461
Study 12655514 — intervention group
Group type: EXPERIMENTAL
Intervention: High p27 expression
Number of subjects: 461
Study 12655514 — intervention group
Group type: EXPERIMENTAL
Intervention: HER-2/neu overexpression
Number of subjects: 461
Study 12655514 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher tumor grade
Number of subjects: 461
Study 12655514 — intervention group
Group type: EXPERIMENTAL
Intervention: Low expression of thymidylate synthase
Number of subjects: 461
Study 12655514 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Ki-67 expression
Number of subjects: 461
Study 9850028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (CCT)
Number of subjects: 6633
Study 9850028 — intervention group
Group type: COMPARATOR
Intervention: Melphalan plus prednisone (MP)
Number of subjects: 6633
Study 7744132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 50 mg bd
Number of subjects: 392
Study 7744132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg bd
Number of subjects: 392
Study 7744132 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 200 mg bd
Number of subjects: 392
Study 7744132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 2661700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg twice per day)
Number of subjects: 151
Study 2661700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 1097490 — intervention group
Group type: EXPERIMENTAL
Intervention: Gerovital H3 (5 ml injection, 3 times a week for first 6 weeks, then 10 ml injection for next 6 weeks)
Number of subjects: 19
Study 1097490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, 5 ml injection, 3 times a week for first 6 weeks, then 10 ml injection for next 6 weeks)
Number of subjects: 19
Study 30728218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441
Study 30728218 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1441
Study 28916443 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ-13 (638.50 mg on days 1 and 2, 319.25 mg on day 3)
Number of subjects: 66
Study 28916443 — intervention group
Group type: COMPARATOR
Intervention: Artemether plus lumefantrine (80 mg artemether and 480 mg lumefantrine twice daily for 3 days)
Number of subjects: 66
Study 28916443 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ-13 (per-protocol analysis)
Number of subjects: 66
Study 28916443 — intervention group
Group type: EXPERIMENTAL
Intervention: AQ-13 (intention-to-treat analysis)
Number of subjects: 66
Study 25091056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation for 14 days before surgery
Number of subjects: 102
Study 25091056 — intervention group
Group type: COMPARATOR
Intervention: Everyday diet (Control)
Number of subjects: 102
Study 22494864 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dietary weight loss
Number of subjects: 38
Study 21559037 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held bioelectrical impedance analysis (HHBIA)
Number of subjects: 98
Study 21559037 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bioelectrical impedance analysis (CBIA)
Number of subjects: 98
Study 21559037 — intervention group
Group type: EXPERIMENTAL
Intervention: Population-specific equation for FFM prediction using CBIA-derived resistance
Number of subjects: 98
Study 21559037 — intervention group
Group type: EXPERIMENTAL
Intervention: Deurenberg equation
Number of subjects: 98
Study 21559037 — intervention group
Group type: EXPERIMENTAL
Intervention: Segal equation
Number of subjects: 98
Study 21559037 — intervention group
Group type: EXPERIMENTAL
Intervention: All BIA methods
Number of subjects: 98
Study 17935647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast iron pots
Number of subjects: 339
Study 17935647 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue steel pots
Number of subjects: 339
Study 17935647 — intervention group
Group type: COMPARATOR
Intervention: Oral iron supplements (control)
Number of subjects: 339
Study 18942523 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg every 12 hours)
Number of subjects: 155
Study 18942523 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (UFH)
Number of subjects: 155
Study 18942523 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH followed by warfarin
Number of subjects: 155
Study 18942523 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH as a bridge therapy
Number of subjects: 155
Study 18942523 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH
Number of subjects: 155
Study 18942523 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 155
Study 14555312 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin (fixed, body-weight-independent dose of 8,000 IU b.i.d. for 8.6 days)
Number of subjects: 1758
Study 14555312 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (IV, adjusted to an 1.5 to 3.0-fold prolongation of the aPTT for 12.0 days)
Number of subjects: 1758
Study 10703934 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT group (n = 145) received a sequential combination of 2 mg estradiol valerate and 1 mg CPA with or without vitamin D3, 100‐300 IU + 500 mg calcium lactate/day (equal to 93 mg Ca2+)
Number of subjects: 322
Study 10703934 — intervention group
Group type: COMPARATOR
Intervention: Non-HRT group (n = 177) received calcium lactate, 500 mg alone or in combination with vitamin D3, 100‐300 IU/day
Number of subjects: 322
Study 10703934 — intervention group
Group type: COMPARATOR
Intervention: Non-HRT group (n = 177) with ER genotypes PP and Pp
Number of subjects: 322
Study 10703934 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT group (n = 145)
Number of subjects: 322
Study 10703934 — intervention group
Group type: COMPARATOR
Intervention: Non-HRT group (n = 177)
Number of subjects: 322
Study 9083708 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone therapy
Number of subjects: 0
Study 9083708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8356542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal hydrophilic gel of methohexital (25 mg/kg)
Number of subjects: 11
Study 8356542 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of methohexital
Number of subjects: 11
Study 3324991 — intervention group
Group type: EXPERIMENTAL
Intervention: Athermic laser therapy (HeNe 632.8 nm and IR diode 904 nm) for 15 minutes over 10 days
Number of subjects: 64
Study 3324991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched-off laser) for 15 minutes over 10 days
Number of subjects: 64
Study 30031217 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release morphine 20 mg
Number of subjects: 23
Study 30031217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 27562713 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored DXA result letter and educational brochure
Number of subjects: 7749
Study 27562713 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 7749
Study 25308301 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 66
Study 25308301 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 66
Study 22928495 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaiazulene (GA) containing local pomade (0.05 g/100 g)
Number of subjects: 30
Study 22928495 — intervention group
Group type: COMPARATOR
Intervention: Extended antifungal treatment (Control)
Number of subjects: 30
Study 20200165 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for silent GERD
Number of subjects: 0
Study 20200165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18843868 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation TKA
Number of subjects: 180
Study 18843868 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 180
Study 16373898 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day ranirestat
Number of subjects: 0
Study 16373898 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/day ranirestat
Number of subjects: 0
Study 16373898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14746386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep phase advanced by 3 hours
Number of subjects: 50
Study 14746386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep phase advanced by 6 hours
Number of subjects: 50
Study 14746386 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of 400 mg of caffeine 30 minutes prior to lights out
Number of subjects: 50
Study 14746386 — intervention group
Group type: COMPARATOR
Intervention: Baseline night (normal sleep)
Number of subjects: 50
Study 10926393 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic-hand-gel regimen
Number of subjects: 32
Study 10926393 — intervention group
Group type: COMPARATOR
Intervention: Soap-and-water hand washing
Number of subjects: 32
Study 9017044 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dorzolamide, 2 drops
Number of subjects: 11
Study 9017044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1997044 — intervention group
Group type: COMPARATOR
Intervention: M6G 30 micrograms kg‐1
Number of subjects: 6
Study 1997044 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G 60 micrograms kg‐1
Number of subjects: 6
Study 1997044 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulphate 120 micrograms kg‐1
Number of subjects: 6
Study 7076516 — intervention group
Group type: EXPERIMENTAL
Intervention: Two meals per day
Number of subjects: 8
Study 7076516 — intervention group
Group type: COMPARATOR
Intervention: Six meals per day
Number of subjects: 8
Study 30835844 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice recruitment strategies
Number of subjects: 5833
Study 30835844 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic and demographic factors
Number of subjects: 5833
Study 30835844 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from GP enrolment to first randomisation
Number of subjects: 5833
Study 29848335 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills building education and multiple micronutrient supplementation (UNIMMAP composition), provided bi-monthly and twice-weekly respectively.
Number of subjects: 0
Study 29848335 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 0
Study 29848335 — intervention group
Group type: EXPERIMENTAL
Intervention: Life skills building education and multiple micronutrient supplementation.
Number of subjects: 0
Study 26414645 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative endorectal balloon (RB) inflation (GII)
Number of subjects: 50
Study 26414645 — intervention group
Group type: COMPARATOR
Intervention: No endorectal balloon (GI)
Number of subjects: 50
Study 24496740 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized spray of neosynephrine/4% plain lidocaine mixture
Number of subjects: 108
Study 24496740 — intervention group
Group type: COMPARATOR
Intervention: Syringe application of neosynephrine/4% plain lidocaine mixture
Number of subjects: 108
Study 24496740 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of disposable spray tips
Number of subjects: 108
Study 24496740 — intervention group
Group type: COMPARATOR
Intervention: Cost analysis of syringes
Number of subjects: 108
Study 22106323 — intervention group
Group type: EXPERIMENTAL
Intervention: 14‐day very low‐calorie diet (VLCD) regimen
Number of subjects: 298
Study 22106323 — intervention group
Group type: COMPARATOR
Intervention: No preoperative dietary restriction (control group)
Number of subjects: 298
Study 19619690 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d prescription omega-3-acid ethyl esters (P-OM3)
Number of subjects: 0
Study 19619690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16413134 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD subjects (childhood trauma)
Number of subjects: 89
Study 16413134 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD subjects (adult trauma)
Number of subjects: 89
Study 16413134 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 89
Study 16413134 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD subjects (both childhood and adult trauma)
Number of subjects: 89
Study 14643578 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 120
Study 14643578 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg / Hydrochlorothiazide 12.5 mg
Number of subjects: 120
Study 14643578 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg / Hydrochlorothiazide 25 mg
Number of subjects: 120
Study 14643578 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 120
Study 14643578 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 120
Study 10932895 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 27
Study 10932895 — intervention group
Group type: COMPARATOR
Intervention: Argon Laser Trabeculoplasty (ALT)
Number of subjects: 27
Study 10932895 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SLT and ALT
Number of subjects: 27
Study 9199728 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration 0.05%
Number of subjects: 18
Study 9199728 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration 0.1%
Number of subjects: 18
Study 9199728 — intervention group
Group type: COMPARATOR
Intervention: Blood alcohol concentration 0.0% (placebo)
Number of subjects: 18
Study 1608850 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg phenytoin
Number of subjects: 31
Study 1608850 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg phenytoin
Number of subjects: 31
Study 1608850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3899397 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (1000 mg single oral dose)
Number of subjects: 100
Study 3899397 — intervention group
Group type: COMPARATOR
Intervention: Quinine plus sulfadoxine-pyrimethamine
Number of subjects: 100
Study 31784339 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (II)
Number of subjects: 42
Study 31784339 — intervention group
Group type: COMPARATOR
Intervention: Typical instruction group
Number of subjects: 42
Study 31067369 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 225
Study 31067369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 28668573 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of whole-virus H7N9 vaccine (30μg HA with aluminum hydroxide adjuvant)
Number of subjects: 200
Study 28668573 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of whole-virus H7N9 vaccine (15μg HA)
Number of subjects: 200
Study 28668573 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of whole-virus H7N9 vaccine (30μg HA without adjuvant)
Number of subjects: 200
Study 28668573 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 25055880 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR-C (continuous at 80% resting systolic blood pressure)
Number of subjects: 12
Study 25055880 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR-I (intermittent at 130% resting systolic blood pressure)
Number of subjects: 12
Study 25055880 — intervention group
Group type: EXPERIMENTAL
Intervention: HL (heavy load at 80% one-repetition maximum)
Number of subjects: 12
Study 25055880 — intervention group
Group type: COMPARATOR
Intervention: LL (light load at 20% one-repetition maximum)
Number of subjects: 12
Study 22889512 — intervention group
Group type: EXPERIMENTAL
Intervention: ADF-HF (45% fat)
Number of subjects: 32
Study 22889512 — intervention group
Group type: COMPARATOR
Intervention: ADF-LF (25% fat)
Number of subjects: 32
Study 21388839 — intervention group
Group type: COMPARATOR
Intervention: Conventional Catheters (CC)
Number of subjects: 10
Study 21388839 — intervention group
Group type: EXPERIMENTAL
Intervention: Manually Steerable Catheters (MSC)
Number of subjects: 10
Study 21388839 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Catheters (RC)
Number of subjects: 10
Study 19185404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus-based regimen
Number of subjects: 53
Study 19185404 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 53
Study 16677265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (2 mg.kg(‐1))
Number of subjects: 45
Study 16677265 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1 mg.kg(‐1))
Number of subjects: 45
Study 16677265 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 45
Study 15320664 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss ball training (2 sessions per week for 6 weeks)
Number of subjects: 18
Study 15320664 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 18
Study 11453262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 126
Study 11453262 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal dinoprostone
Number of subjects: 126
Study 9241338 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide in oxygen (2:1) supplemented with fentanyl (Control)
Number of subjects: 60